Brief: Sequana Medical Completes Enrollment In Phase 2A Sahara I DSR Study

Sequana Medical NV

19/07/2022 06:06

July 19 (Reuters) - Sequana Medical NV  SEQUA.BR :
    * SEQUANA MEDICAL COMPLETES ENROLLMENT IN PHASE 2A SAHARA I
DSR
STUDY, REPORTS DISEASE-MODIFYING PROFILE FOR SHORT TERM DSR AND
PROVIDES BUSINESS UPDATE
    * SUBMISSION OF PREMARKET APPROVAL (PMA) TO US FDA EXPECTED
IN H2
2023
    * CLINICAL OUTCOMES FROM RED DESERT AND SAHARA RESULT IN A
75%
REDUCTION IN PREDICTED ONE-YEAR MORTALITY BASED ON SEATTLE HEART
FAILURE MODEL(III)
    * POSEIDON, NORTH AMERICAN PIVOTAL STUDY OF ALFAPUMP IN
RECURRENT
AND REFRACTORY ASCITES DUE TO LIVER CIRRHOSIS IS ON TRACK TO
REPORT PRIMARY ENDPOINT DATA IN Q4 2022
    * SEQUANA MEDICAL INTENDS TO EXTEND SAHARA TO TREAT A SMALL
NUMBER
OF PATIENTS WITH ITS PROPRIETARY SECOND-GENERATION DSR PRODUCT

Source text for Eikon:  ID:nGNE4Kp1YL 
Further company coverage:  SEQUA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))